ELVN insider sale: 12,500 shares at $22.082 via plan

Rhea-AI Filing Summary

Enliven Therapeutics (ELVN) reported an insider transaction by its Chief Scientific Officer on Form 4. The filing shows a sale of 12,500 shares of common stock on October 20, 2025 at a weighted average price of $22.082, executed under a Rule 10b5-1 trading plan adopted on November 15, 2024. Following the sale, the reporting person beneficially owned 915,188 shares, held indirectly through The Lyssikatos Revocable Trust dated 12/15/2011.

The transaction price ranged from $21.285 to $22.36, with full trade details available upon request.

Insider Trade Summary

Net Seller: 12,500 shares ($276,025)

Net Sell 1 txn

Insider Lyssikatos Joseph P

Role CHIEF SCIENTIFIC OFFICER

Sold 12,500 shs ($276K)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,500	$22.082	$276K

Holdings After Transaction: Common Stock — 915,188 shares (Indirect, See footnote)

Footnotes (1)

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. This transaction was executed in multiple trades at prices ranging from $21.285 to $22.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lyssikatos Joseph P

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/20/2025		S(1)		12,500	D	$22.082(2)	915,188	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

2. This transaction was executed in multiple trades at prices ranging from $21.285 to $22.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

	/s/ Ben Hohl, by power of attorney	10/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ELVN disclose in this Form 4?

An insider sale by the Chief Scientific Officer of 12,500 shares of common stock on October 20, 2025.

At what price were the ELVN shares sold?

The weighted average sale price was $22.082, with trades ranging from $21.285 to $22.36.

Was the ELVN sale under a 10b5-1 plan?

Yes. The sales were effected under a Rule 10b5-1 trading plan adopted on November 15, 2024.

How many ELVN shares are beneficially owned after the sale?

The reporting person beneficially owned 915,188 shares after the transaction.

How are the remaining ELVN shares held?

They are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which the reporting person serves as trustee.

What is the insider’s role at ELVN?

The reporting person is an Officer, serving as Chief Scientific Officer.